Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5698_Библиотеки_им_академика_М_И_Перельмана
.pdf
N
Nanocapsules, 43
Nanocarriers
herbal control drug delivery
classification and synthesis, 167e168
clathrin-coated vesicles (CCV), 164e165
clathrin-mediated endocytosis (CME), 164e165
definition, 163
ethosomes, 168e175
folate-decorated poly (ethylene glycol)-
polycaprolactone nanoparticles, 165e166
formulations for, 169te174t
hybrid herbal nanomaterials, 179e181
internalization pathways, 166e167, 166f
liposomes, 168
macropinocytosis, 164
natural products incorporation, 164
new formulations, 163
niosomes, 175
phagocytosis, 164
phytosomes and transferosomes, 175
size, 164
phytoconstituent delivery, neurodegenerative
disorders (NDs), 407te409t
carbon nanotubes (CNTs), 412
cubosomes, 410
dendrimers, 410
hybrid nanocarrier, 412e413
inorganic nanocarrier, 410e412
liposomes, 406
mesoporous silica nanoparticles (MSNs), 411e412
metal nanoparticles, 411
nanocrystals (NCs), 410
nanomicelles, 412
organic nanocarriers, 406e410
polymeric nanoparticles/nanocapsules/
nanospheres, 406
self-microemulsifying drug delivery systems
(SMEDDS), 406
solid lipid nanoparticles (SLNs), 409e410
for post-COVID-19 complications, 182t
Nanocrystals (NCs), neurodegenerative disorders
(NDs), 410
Nanoemulsion
advantages, 204f
for phytopharmaceuticals delivery, 203e204
Nanofibers, 146e147
Nanomedicine, 159
Nanomicelles, neurodegenerative disorders (NDs),
412
Nanoparticles, berberine (BER), 380e381
Nanophytomedicines
nanoparticle (NP)
ayurveda, 148
carbon nanotube, 147
cubosomes, 145
dendrimers, 147
dimensions, 141
human serum albumin, 146
hydrogels, 146
lipid nanoparticles, 145
metal nanoparticles (MNPs), 144e145
micelles, 147
nanocapsules, 141
nanofibers, 146e147
phospholipid complex, 147
polymeric nanoparticles, 142e
144
self-assembled nanosystems, 145
self-nanoemulsifying drug delivery systems
(SNEDDS), 146
particulate nanosystems
lipid nanoparticles, 200e201
metallic nanoparticles, 201
phytochemicals, 199e200
polymeric nanoparticles, 200
phytoactives, 141f
vesicular nanosystems
liposomes, 201e202
niosomes, 202, 202t
phytosomes, 202
transferosomes, 202e203
Nanoscaffolds, berberine (BER), 384
Nanospheres, 43
Nanostructured lipid carriers (NLCs), 48e50, 94e96
berberine (BER), 380e381
polyphenol-loaded, melanoma treatment, 349e350
Nanosystems, 42f
Nanotechnology, 155e156
advantages, 41
applications, 183f
based herbal product
bioavailability enhancement, 195e196
development and value addition, 194e199
marketing herbal product, 198e199
nanocarriers, 195f
shelf-life improvement, 198
stability issues, 196e197
definition, 159
enhanced permeability and retention (EPR) effect,
42e43
lipid-based nanoparticles, 45e53
nanocarriers, 41e42
nanomaterials, 157e158
nanonization techniques, 140
nanoparticles, 41e42
novel drug delivery systems (NDDS), 157e158
Index458
https://t.me/med1917
pharmaceutical nanocarriers systems, 140
plant actives/derivatives formulations, 41t
polymeric nanoparticles, 43e45
receptors, 43
Nanotheranostic agents, 179, 179f
Naringenin (NAR), 434e435, 434f
Naringin
anti-inflammatory properties, 436
biological impacts, 435
phenylpropanoid pathway, 435
Natural active ingredients, 31
Natural compounds
antiinflammatory properties, 36
biological activities, 33te34t
and cancer, 32e35
and infectious diseases, 35e36
limitations, 39
therapeutic potential, 31e36
Natural products
market trend, 3e4
research in, 2e3
Nature-based bioactives, 135
Naturex, 284e287
Nectandra membranacea, 305
Nektium, 288
Nerve growth factor (NGF), 325e326
Neurapas, 318e319
Neurodegenerative disorders (NDs)
amyotrophic lateral sclerosis (ALS), 401e402
Huntington disease (HD), 400e401
incidences, 396
nanodrug delivery systems, 396
neurodegeneration, 395e396
Parkinson disease (PD), 399
phytoconstituent delivery
approaches, 404f
nanocarriers, 405e413
nose-to-brain drug delivery (NBDD), 404
polymer- and lipid-based nanoformulations,
405
polyphenols, 405
phytomedicines for, 397e402
spinal muscular atrophy (SMA), 402
spinocerebellar ataxia (SCA), 402
Neuroprotection, polyphenols, 138
Neutralization precipitation method, phyto-
complexes, 121
Niosomes
herbal control drug delivery, 175
neurodegenerative disorders (NDs), 406
phytopharmaceuticals delivery, 202
Nitrogen-containing compounds, 280
Nose-to-brain drug delivery (NBDD), 404
Novel drug delivery systems (NDDS), 4
Nutraceuticals, 281
O
Opaxio, 44
Organic herb Inc., 288
Organoleptic properties, 216
Organ-on-a-chip systems
cytotoxicity screening, 319
microfluidic. See Microfluidic organ-on-a-chip
systems
nutraceutical components screening and extraction,
318e319
photomask microfabrication, 321f
single cell-based microfluidic biochip, 319e321
Organosulfur compounds, 280
Oxidative damage, 276e277
P
Paclitaxel (Taxol), 34e35
Panax ginseng, antioxidant property, 19e21
Papaver somniferum,31e32
Parkinson disease (PD)
medicinal plants, 400t
movement abnormalities, 399
phytomedicines, pathophysiological targets, 399f
Particulate system, 94e95
Passiflora edulis f. flavicarpa, 305
Peumus boldus, 305e306
Phagocytosis, 164, 425
Pharmaceutical challenges, 225
Pharmacodynamic interactions, 247, 248t
Pharmacokinetic evaluation, botanicals, 262e263
Pharmacokinetic interactions, 300e301
absorption, 246
absorption level, 300
distribution, 246
distribution level, 300
enzyme induction, 301
enzyme inhibition, 301
excretion, 247
excretion level, 301
metabolism, 247
metabolism (biotransformation) level, 301
Pharmacokinetics, 83te84t
Pharmacological antagonism, 300
Pharmacosome, 177t
Phenolic compounds, 279
Phenylpropanoids, 32
Phosphatidylcholine (PHC), 118
Phospholipid complex, 118, 147
Phospholipid phyto-complex, 113te115t
Physical antagonism, 300
Index 459
https://t.me/med1917
Physical blending method, phyto-complexes, 120
Phytochemicals, 112
alkaloids, 280
bioactive nutraceuticals, 317e318
carcinogen metabolism, 277
carotenoids, 279
classification, 279
contemporary scenario, 281
disease treatment, 277
global market, 282e283
health benefits, 276e277
Indian market, 290te292t
international key players, 283e284
international market, 285te286t
market demand, 281
market potential. See Market potential
nitrogen-containing compounds, 280
organosulfur compounds, 280
phenolic compounds, 279
secondary metabolites, 317
therapeutic applications, 317
worldwide demands, 282
Phyto-complexed systems
applications, 124e126
characterization, 122e124
chitooligosaccharides, 113te115t
cyclodextrins, 113te115t
molecular complexes
chitooligosaccharide complex, 119
cyclodextrin complexes (CDs), 115e116
inclusion complexes (ICs), 115
noncovalent interactions, 115
phospholipid complexes, 118
phospholipids, 113te115t
preparation
atomization/spray-drying method, 122
coprecipitation technique, 121
kneading method, 121
lyophilization/freeze-drying method, 122
microwave irradiation method, 121
milling/cogrinding method, 121
neutralization precipitation method, 121
physical blending method, 120
solvent evaporation technique, 119e120
therapeutic uses, 126
Phytocompounds
formulations, 13
pharmacological properties, 13
plant metabolites, 12
terpenoids, 13
Phytoconstituents/bioactives
bioavailability, 139
release pattern, 139
solubility, 138e139
stability, 139
Phytomedicine, 194
acute disease treatment, 17
antiinflammatory agents, 17e19
antimicrobial infections, 22e23
antineuropathic and antitumor activity, 21e22
antioxidant property, 19e21
chronic disease treatment, 16e17
Phytonics process, 88
Phytopharmaceutical drug, 210
Phytosomes, 94
composition, 52e53
domperidone-loaded, 52e
53
gingerol, 52e53
herbal control drug delivery, 175
metallic nanoparticles, 53e55
phytopharmaceuticals delivery, 202
Piperine, 7te8t
Pisidium guajava, 306
Plant actives
commercialized drug-based, 38t
conventional pharmaceutical formulations, 36e37
drug delivery system
ethosomes, 52
lipid-based micelles, 51
lipid nanocapsules (LNCs), 50e51
liposomes, 45e48
nanostructured lipid carriers (NLCs), 48e50
nanotechnology, 40e56
phytosomes, 52e53
solid lipid nanocarriers (SLNs), 48e50
transfersomes, 51
and extracts, 82
formulation development, screening models
ex vivo assays, 59
in silico assays, 56e58
in vitro cell culture systems, 58
in vivo studies, 59e61
limitations, 39, 39f
market, 36e37
nanotechnology, 39f
pharmaceutical formulations, 40
regulatory framework, 62t
drug approval, 63
food supplements, 61
traditional use registration, 62
Podophyllum hexandrum, 310e311
Polyherbal formulation, 261
Polyketides, 32
Polymeric micelle, berberine (BER), 382e383
Polymeric nanoparticles
nanocapsules and nanospheres, 43
Index460
https://t.me/med1917
natural polymers, 44
neurodegenerative disorders (NDs), 406
opaxio, 44
plant actives/derivatives delivery, 46t
polyphenol-loaded, melanoma treatment, 350e352
smart drug delivery, 44
Polyphenols
anticarcinogenic activities, 137e138
antioxidant activity, 136e137
cardioprotection activity, 137
neuroprotection, 138
Preformulation
compatibility, 216
good agricultural and collection practices (GACP)
guidelines, 214e215
herbal drug-herbal drug interaction, 216
herbal-drug interaction, 216e217
hygroscopicity, 215
laxative effect, 216
need of, 212f
organoleptic properties, 216
quality control
adulteration of botanical preparations, 213
chemical ingredient, 214
environmental factors, 214
herbal drugs, 213e214
medicinal plants, 212e213
parameters, 212e213
solubility and dispensability, 215
standardization, 215
therapeutic molecule characterization, 211e212
Pressured liquid extraction (PLE), 88e89
Primary effusion lymphoma (PEL), 16e17
Primary metabolites, 159
Proanthocyanidins (PAC), 432e433, 433f
Proliposome, 94
Puerarin, 58
Pulsed electric field extraction (PEFE) technique, 89
Q
Quercetin, 7te8t
for inflammatory disorders, 430
neuroprotective bene?ts, 22
Quillaja saponaria Mol., 160
Quinine, 209e210
R
Radiopharmaceuticals interactions
diagnostic purposes, 297e298
and herbal medicines, 308te310t
aloe vera, 302
Annona muricata, 302
Arctium lappa, 303
Artemisia vulgarisi L., 303
broccoli, 303
Caryophyllus aromaticus L., 304
Cassia angustifolia, 304
Cinnamomum zeylanicum, 304
Ginkgo biloba, 305
Hypericum perforatum, 305
Nectandra membranacea, 305
Passiflora edulis f. flavicarpa, 305
Peumus boldus, 305e306
Pisidium guajava, 306
Rosmarinus officinalis, 306
Sechium edule, 306
Thuya occidentalis, 306e307
Uncaria tomentosa, 307
properties, 298
radioactive labeling, 299
radionuclides, 299
Radioprotection
broccoli, 307
Ginkgo biloba, 307
Malpighia glabra, 310
Podophyllum hexandrum, 310e311
Reactive oxygen species (ROS), 276e277
Regulatory challenges, 225
Repeated-dose toxicity test, 220e221
Resveratrol (RES), 7te8t, 54te55t, 428e429, 429f
Rosmarinic acid
antineuropathic activity, 21e22
antitumor activity, 21e22
Rutin, 7te8t, 54te55t
S
Safety issues
clinical studies, 210e211
manufacturing standards, 210e211
novel delivery systems, 228e229
regulatory requirements, 210
safety issues, 211e228
altered pharmacokinetics, 227
formulation and development issues, 226e227
formulation issues, 227
instability, 226
lipid solubility and bioavailability, 226
medicinal plant-related challenges, 225
natural products delivery, 224e228
pharmaceutical challenges, 225e228
preformulation issues, 211e217
regulatory challenges, 225
shelf-life assessment issues, 227e228
toxicity issues, 217e224
Scanning electron microscopy, phyto-complexes, 124
Sebaceous glands, 336
Index 461
https://t.me/med1917
Sechium edule, 306
Secondary metabolites, 159e160
Self-assembled nanosystems, 145
Self-assembled polymer system, berberine (BER), 382
Self-nanoemulsifying drug delivery systems
(SNEDDS), 146
Shelf-life assessment issues, 227e228
Shelf-life improvement, 198
Silybin, 96
Silymarin, 117te118t
Silymarin lipid nanoemulsion formulations, 93
Sinapic acid (SA), 428
Single cell-based microfluidic biochip, 319e321, 321f
Single-dose toxicity (acute toxicity), 219e220
Skin
anatomy, 335e336
appendages, 336
dermis, 336
epidermis, 336
Langerhans and dendritic cells, 336
physiology, 335e336
structures and components, 335f
Skin cancer, 334e335
Solid dispersion, berberine (BER), 381
Solid lipid nanocarriers, 48e50
advantages, 49e50
thermoresponsive, 49
Solid lipid nanoparticles (SLNs), 85te86t
berberine (BER), 380e381
neurodegenerative disorders (NDs), 409e410
polyphenol-loaded, melanoma treatment, 349e350
Solvent evaporation, 100, 119e120
Sphingosine, 177t
Spinal muscular atrophy (SMA), 402
Spinocerebellar ataxia (SCA), 402, 403t
Stability study
interactions issues, 233e234
microbial tests, 238
physical and sensory tests, 238
rate constant, 232
regulatory aspects, 236e238
safety and toxicity parameters test, 239
St. John’s wort, 305
Storage and stability issues
analytical method development, 231e232
biochemical composition variability, 230
chemical complexity, 230
chemical markers, 229e231
chemical reactions, 232
contaminants, 230e231
enzymatic activities, 232
multiconstituent-based herbal products, 229
shelf life assessment, 231
Stratum corneum (SC), 336
Subacute toxicity, 221
Subchronic toxicity, 221
Sulfur-containing organic compounds, 280
Supercritical fluid extraction methods (SFE), 87
Superparamagnetic iron oxide nanoparticles
(SPIONs), 180e181, 348
Surface morphology, phyto-complexes, 124
Sydler, 289
Synthetic drugs, 1
T
Tamarindus indica,22e23
Targeted/site-specific phytopharmaceuticals delivery,
228
Terpenoids, 32
Thuya occidentalis, 306e307
Tiliroside, 117te118t
Toxicity issues
chromosomal damage test
carcinogenicity tests, 223
immunotoxicity and antigenicity tests, 223e224
mammalian bone marrow chromosome aberration
test, 222e224
reproductive and developmental toxicity tests, 223
rodent hematopoietic cells, 222e224
safety pharmacology studies, 224
toxicokinetic studies, 223
data assessment
administration route, 219
contaminants, 219e220
dose levels/concentrations, 219
preclinical testing, 218
sample size, 218
testing strategy, 219
test models, 218
minimal toxicity test battery, 217
toxicity test battery
Ames test, 222
brine shrimp (Artemia salina) lethality assay, 221
chronic toxicity, 221
cytotoxicity tests, 222
enotoxicity tests, 222
genotoxicity test, 222
repeated-dose toxicity test, 220e221
single-dose toxicity (acute toxicity), 219e220
subacute toxicity, 221
subchronic toxicity, 221
Toxicokinetic studies, 223
Traditional medicine, 11
Transdermal delivery, polyphenols
advantages, 345t
limitations, 345t
Index462
https://t.me/med1917
melanoma treatment
inorganic nanoparticles, 352
lipid-based nanoparticles, 349e350
liposomes, 349
nanocarrier formulations, 343f
nanoencapsulation, 342e345
nanoparticles penetration, 345e347
polymer nanoparticles, 350e352
size and surface charge, 344
topically applied nanoparticulate, 346
toxicity considerations, 353
transappendageal route, 346
Transferosomes
herbal control drug delivery, 175
neurodegenerative disorders (NDs), 406
phytopharmaceuticals delivery, 202e203
Transfersomes, 51
Trehalose, 400e401
Tumorigenesis, 339e341
U
UHPLC-Orbitrap method, 278
Ultrasonication-assisted extraction (UAE), 87e88
Uncaria tomentosa, 307
V
Vesicular drug delivery systems, herbal control drug
delivery, 175e176
Vesicular nanocarriers, 175e176
Vesicular nanosystems
liposomes, 201e202
niosomes, 202, 202t
phytosomes, 202
transferosomes, 202e203
Vesicular system, 40, 85te86t, 93e94
Vincristine, 93
Vincristine-loaded liposomes, 45e48
Virosome, 177t
W
Withaferin-A, 22
X
Xenograft B-lymphoma model, 45e48
X-ray crystallography, phyto-complexes, 124
X-ray powder diffraction, phyto-complexes, 123
Y
Yogavedic therapies, 13
Z
Zingiber officinale, antiinflammatory capabilities,
18e19
Index 463
https://t.me/med1917
This page intentionally left blank
https://t.me/med1917
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана